COMMUNIQUÉS West-GlobeNewswire

Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)
27/11/2018
Biosimilar Ziextenzo ® (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications [1] Ziextenzo is indicated to reduce duration of [...]
Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London
27/11/2018
Alcon is the global leader in the highly attractive and growing $23 billion eye care devices market Market leading development capabilities and innovation investments Clearly defined near and long-term strategy, focused [...]
Sensorion Announces Completion of Patient Enrollment and Dosing in Seliforant Phase 2a Study
27/11/2018
First results are expected by the end of the year MONTPELLIER, France, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN) , a clinical-stage biopharmaceutical company specializing in the treatment of [...]
Amarin Prices Public Offering of American Depositary Shares
27/11/2018
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced the pricing of the underwritten public offering of its American Depositary Shares ("ADSs") [...]
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)
27/11/2018
First treatment with a tumor-agnostic indication at the time of initial FDA approval 75% overall response rate (ORR) (95% CI, 61%, 85%) [22% complete response (CR) and 53% partial response (PR)] across various solid [...]
Oxford Immunotec to Participate in Two Investor Conferences This Week
26/11/2018
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief [...]
Akorn Receives Product Approval
26/11/2018
LAKE FOREST, Ill., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that it received a new Abbreviated New Drug Application (ANDA) approval from [...]
Canopy Rivers Reports Second Quarter Financial Highlights and Provides Corporate Update
26/11/2018
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES TORONTO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (the “ Company ” or “ Canopy Rivers ”) (TSXV: RIV) today released its financial results [...]
XORTX Receives FDA Response on Orphan Drug Designation Application
26/11/2018
Pivotal Phase 2/3 Clinical Study in ADPKD Planned in 2019 CALGARY, Alberta, Nov. 26, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company [...]
Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors
26/11/2018
WARMINSTER, Pa., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Frank Torti has been [...]
IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018
26/11/2018
DARTMOUTH, Nova Scotia, Nov. 26, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it will present data on its DPX-RSV program at “ RespiDART: [...]
Molecular Templates to Present at the Evercore ISI and BMO Healthcare Conferences
26/11/2018
AUSTIN, Texas, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies [...]
Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief Executive Officer
26/11/2018
COLUMBIA, Md., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, [...]
Abeona Therapeutics Announces CEO Transition
26/11/2018
Dr. Carsten Thiel to Depart Company Immediately; Dr. João Siffert Appointed Interim CEO NEW YORK and CLEVELAND, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage [...]
Abattis Bioceuticals Celebrates Release of Comfort Through Vergence Naturals
26/11/2018
VANCOUVER, British Columbia, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp (the “ Company ” or “ Abattis ”) (CSE:ATT) (OTC:ATTBF) is pleased to announce the release of its first proprietary product, [...]
Amarin Announces Proposed Public Offering of American Depositary Shares
26/11/2018
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced a registered underwritten public offering of its American Depositary Shares (“ADSs”). All of [...]
Transparency notification
26/11/2018
Mechelen, Belgium; 26 November 2018; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Van Herk Investments B.V . Pursuant to Belgian transparency [...]
G1 Therapeutics Announces Positive Myelopreservation Data from Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Trilaciclib in Combination with Chemotherapy/Tecentriq® in First-Line Small Cell Lung Cancer
26/11/2018
Second randomized, double-blind, placebo-controlled Phase 2 trial confirms multi-lineage myelopreservation benefits of trilaciclib in first-line small cell lung cancer (1L SCLC) Statistically significant improvements in [...]
CareDx Strengthens Executive Leadership Team with the Appointment of Reginald Seeto, MB.BS, as President and Chief Business Officer
26/11/2018
BRISBANE, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high- [...]

Pages